Bristol-Myers Squibb는 종양학 및 면역학 분야의 생물의약품 리더로서 강력한 배당금 성장 실적을 갖추고 있으며, 강력한 인수 중심의 파이프라인 전략으로 특허 절벽을 극복해 나가고 있습니다.
Bristol-Myers Squibb는 제약 산업에서 매력적이고 평균 이상의 배당 수익률을 제공하며, 확립된 의약품 포트폴리오에서의 강력한 자유 현금 흐름 창출과 주주 환원 약속으로 뒷받침됩니다.
Bristol-Myers Squibb는 종양학, 심혈관, 면역학, 섬유화에 걸친 블록버스터 의약품의 다양한 포트폴리오를 갖춘 최상위 글로벌 제약회사로서, 매년 수백억 달러의 매출을 창출합니다.
Data updated Feb 15 · Source: Twelve Data
Bristol-Myers Squibb has shown impressive recent momentum, surging nearly 35% over the past 90 days and trading near its 52-week high of $63.33. However, the 5-year return of just 1.64% highlights the longer-term challenges this large-cap pharma has faced, including patent cliffs on key drugs like Revlimid and Eliquis.
The P/E ratio of 28.65 appears elevated for a mature pharmaceutical company, though this may reflect depressed earnings from recent acquisitions and restructuring costs. BMY's dividend remains a cornerstone of the investment thesis, with a yield around 4% and a strong track record of consecutive increases befitting its Dividend Aristocrat status.
Bull case: Growing oncology and immunology pipeline (including Opdivo and recent acquisitions like Karuna Therapeutics), attractive dividend yield, and potential earnings recovery. Bear case: Significant revenue headwinds from patent expirations through 2026, heavy debt from acquisitions, and execution risk integrating new assets. BMY suits income-oriented investors willing to accept near-term uncertainty for a solid dividend and pipeline optionality.
Bristol-Myers Squibb presents a compelling value proposition within the pharmaceutical sector. Trading at a P/E ratio of roughly 11.9, the stock is priced conservatively, reflecting investor caution regarding the significant "patent cliff" facing legacy blockbusters like Revlimid and Eliquis. However, BMY is successfully executing a strategic pivot toward its new growth portfolio, including promising assets like Reblozyl and Camzyos. The stock's recent recovery from 52-week lows indicates warming market sentiment toward this turnaround story. For income-focused investors, BMY remains a standout choice due to its robust cash flow and reliable dividend history. While execution risks persist regarding pipeline delivery and debt management following recent acquisitions, the current valuation provides a reasonable margin of safety. BMY is well-suited for conservative investors seeking consistent yield and long-term capital appreciation.
Latest from Otrai
A stock index is a single number that summarizes the price action of a basket of companies. The S&P 500 tracks roughly 500 large US firms, the Nasdaq-100 tracks the 100 largest non-financial names on the Nasdaq exchange, and the Dow Jones Industrial Average follows 30 blue-chip stocks.
The Greeks explain why an option costs what it costs and how that price changes when the stock moves, time passes, and volatility shifts. Delta, Gamma, Theta, and Vega, made accessible.
Chart patterns are the most recognizable part of technical analysis and the most misunderstood. Most fail or break out the wrong way before reversing. This guide covers head and shoulders, double tops and bottoms, triangles, and flags — with realistic reliability, target measurement, and false-breakout confirmation.
모든 트레이더는 머릿속으로는 훌륭해 보이는 전략을 가지고 있습니다. 백테스팅은 실제로 작동하는지 알아내는 방법입니다. 여기서는 전략을 올바르게 테스트하는 방법, 어떤 지표가 중요한지, 그리고 대부분의 백테스트 결과가 사실이기에는 너무 좋은 이유를 보여줍니다.
Powered by Rexiew